1![Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th](https://www.pdfsearch.io/img/82997e89fc85299534b4d6b5ce91f517.jpg) | Add to Reading ListSource URL: apac-asia.comLanguage: English - Date: 2017-05-01 03:53:28
|
---|
2![EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin](https://www.pdfsearch.io/img/6f7bb2e184a43506aec1add58999275b.jpg) | Add to Reading ListSource URL: www.piqur.com- Date: 2016-02-17 03:09:52
|
---|
3![EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i](https://www.pdfsearch.io/img/1613aa05e13d112c8e65ff4ecbaee9ff.jpg) | Add to Reading ListSource URL: www.piqur.comLanguage: English - Date: 2016-02-17 03:09:52
|
---|
4![Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer](https://www.pdfsearch.io/img/d80b50351e3438e37683ceaee9ddc12d.jpg) | Add to Reading ListSource URL: cancer.ucsf.eduLanguage: English - Date: 2014-10-06 14:59:53
|
---|
5![January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in](https://www.pdfsearch.io/img/34b39689b5e2847e103369668bde9aa6.jpg) | Add to Reading ListSource URL: www.eisai.comLanguage: English - Date: 2015-01-13 01:46:50
|
---|
6![State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VTwww.dvha.vermont.gov State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 Williston, VTwww.dvha.vermont.gov](https://www.pdfsearch.io/img/6217adb4d2e3b28b5b053bd2dab4c338.jpg) | Add to Reading ListSource URL: dvha.vermont.govLanguage: English - Date: 2015-02-20 16:02:44
|
---|
7![SCHEDULE OF PHARMACEUTICAL BENEFITS EFFICIENT FUNDING OF CHEMOTHERAPY – SECTION 100 ARRANGEMENTS SUPPLEMENT This schedule is also available on the internet at www.pbs.gov.au SCHEDULE OF PHARMACEUTICAL BENEFITS EFFICIENT FUNDING OF CHEMOTHERAPY – SECTION 100 ARRANGEMENTS SUPPLEMENT This schedule is also available on the internet at www.pbs.gov.au](https://www.pdfsearch.io/img/d2a3f96191f6ca921dfc657abb68e437.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-02 00:13:48
|
---|
8![Microsoft Word[removed]Eribulin Eisai PSD March 13 final.docx Microsoft Word[removed]Eribulin Eisai PSD March 13 final.docx](https://www.pdfsearch.io/img/634748c785128f92b6ce2951b7aabadc.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2015-03-06 00:23:42
|
---|
9![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use See full prescribing HALAVEN® safely and effectively. information for HALAVEN. HALAVEN® (eribulin mesylate) Inject HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use See full prescribing HALAVEN® safely and effectively. information for HALAVEN. HALAVEN® (eribulin mesylate) Inject](https://www.pdfsearch.io/img/88e96706e67040ee75e7c534fc30bac4.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-08-04 14:23:47
|
---|
10![U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived](https://www.pdfsearch.io/img/eac4ad810d5890fc08c9cfe6d23a3ebd.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|